Companies › NKGen Biotech
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Neurology; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SNK01 autologous natural killer (NK) cell therapy, patient-specific ex vivo expanded | – | Phase 2 | Alzheimer Disease; Moderate Alzheimer Disease | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06189963 | SNK01 | Phase 1 | Moderate Alzheimer Disease | Neurology | Mar 2028 |
| NCT07228078 | SNK01 | Phase 2 | Alzheimer Disease | Neurology | Apr 2028 |
No annotated target.
–
Cytopeutics Sdn. Bhd. Sandoz Merz Pharmaceuticals Lupin Neurona Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.